| Literature DB >> 28671564 |
Carlos Urda1, Rogelio Fernández2, Jaime Rodríguez3, Marta Pérez4, Carlos Jiménez5, Carmen Cuevas6.
Abstract
Two novel oxazole-thiazole containing cyclic hexaEntities:
Keywords: Lissoclinum bistratum; Zn complex; bistratamides; cyclic hexapeptides; cytotoxic; sponge
Mesh:
Substances:
Year: 2017 PMID: 28671564 PMCID: PMC5532651 DOI: 10.3390/md15070209
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Chemical structures of compounds 1–4.
NMR data of 1 and 2 in CDCl3 (500 MHz for 1H and 125 MHz for 13C).
| No. | Bistratamide M (1) | Bistratamide N (2) | ||
|---|---|---|---|---|
| 1 | 159.7, C | - | 159.0, C | - |
| 2 | 135.5, C | - | 135.6, C | - |
| 3 | 141.9, CH | 8.27, s | 141.5, CH | 8.23, s |
| 4 | 164.3, C | - | 164.6, C | - |
| 5 | 44.2, CH | 5.38, m | 44.1, CH | 5.37, m |
| 6 | 19.9, CH3 | 1.72, d (7.1) | 20.8, CH3 | 1.72, d (6.8) |
| 7 | 159.4, C | - | 159.5, C | - |
| 8 | 149.2, C | - | 149.1, C | - |
| 9 | 123.0, CH | 8.12, s | 123.3, CH | 8.12, s |
| 10 | 167.1, C | - | 167.9, C | - |
| 11 | 55.3, CH | 5.44, m | 54.9, CH | 5.54, m |
| 12 | 40.1, CH | 2.18, m | 41.5, CH | 2.09, m |
| 13 | 26.3, CH2 | 1.63, m; 1.24, m | 25.6, CH2 | 1.67, m; 1.32, m |
| 14 | 11.5, CH3 | 1.01, t (7.4) | 11.6, CH3 | 1.02, t (7.4) |
| 15 | 14.5, CH3 | 0.87, d (6.8) | 15.1, CH3 | 0.97, d (6.8) |
| 16 | 159.8, C | - | 159.8, C | - |
| 17 | 148.2, C | - | 148.6, C | - |
| 18 | 125.0, CH | 8.22, s | 124.3, CH | 8.17, s |
| 19 | 171.6, C | - | 171.0, C | - |
| 20 | 48.2, CH | 5.40, m | 47.7, CH | 5.46, m |
| 21 | 23.9, CH3 | 1.74, d (6.9) | 24.8, CH3 | 1.75, d (6.7) |
| NH-1 | - | 8.69, d (5.7) | - | 8.71, d (6.5) |
| NH-2 | - | 8.64, d (7.2) | - | 8.65, d (7.3) |
| NH-3 | - | 8.42, d (8.0) | - | 8.46, d (9.0) |
Figure 2COSY correlations (displayed by bold bonds) and key HMBC (arrows) in 1 and 2.
Figure 3Partial 13C NMR spectra of compound 3 after addition of a ZnCl2 solution: (a) 4 equiv.; (b) 2 equiv.; and (c) 0 equiv. in CD3CN.
Figure 4Partial 1H NMR spectra of (a) compound 3 and (b) after addition of a 4 equiv. ZnCl2 solution in CD3CN.
Figure 5(A) Experimental (top) and calculated (bottom) isotopic clusters of compound 3 after addition of a 4 equiv. ZnCl2 solution detected in its (+)-ESI-TOFMS. (B) Structure proposal for a mononuclear Zn2+ complex of 3.
Cytotoxic activity data (μM) of 1 and 2.
| Compound | Cell Line | ||||
|---|---|---|---|---|---|
| Breast | Colon | Lung | Pancreas | ||
| MDA-MB-231 | HT-29 | NSLC A-549 | PSN1 | ||
| GI50 | 18 | 16.0 | 9.1 | 9.8 | |
| TGI | >20.0 | >20.0 | >20.0 | >20.0 | |
| LC50 | >20.0 | >20.0 | >20.0 | >20.0 | |
| GI50 | >20.0 | 13.0 | 11.0 | 15.0 | |
| TGI | >20.0 | >20 | >20.0 | >20.0 | |
| LC50 | >20.0 | >20 | >20.0 | >20.0 | |
| GI50 | 0.2 | 0.3 | 0.2 | 0.2 | |
| TGI | 0.5 | 0.9 | 0.9 | 0.5 | |
| LC50 | 2.4 | >17.2 | >17.2 | 3.1 | |
GI50, compound concentration that produces 50% inhibition on cell growth as compared to control cells; TGI, compound concentration that produces total growth inhibition as compared to control cells, and LC50, compound concentration that produces 50% cell death as compared to control cells.